Search Results - "Wahner Hendrickson, A.E."

756P First-in-human phase I study of a novel claudin 6 (CLDN6) targeted antibody drug conjugate (ADC) TORL-1-23 by Konecny, G.E., Wahner Hendrickson, A.E., Winterhoff, B., Machado, A., Chander, C., Davenport, S., Bilic, S., Miller, L-L., Chung, A., Press, M.F., Letrent, S., Slamon, D.

Get full text

Safety and Efficacy Results of Retreatment With a PARP Inhibitor Monotherapy in Late-Line Recurrent Ovarian Cancer: Results From a Subset of the QUADRA Trial by Rimel, B.J., Secord, A.A., Geller, M.A., Miller, D.S., Cloven, N., Fleming, G.F., Hendrickson, A.E. Wahner, Azodi, M., DiSilvestro, P., Oza, A.M., Cristea, M., Berek, J.S., Chan, J.K., Matei, D.E., Li, Y., Sun, K., Luptakova, K., Matulonis, U.A., Monk, B.J., Moore, K.N.

Get full text

LBA60 - Randomized phase II (RP2) study of ATR inhibitor M6620 in combination with gemcitabine versus gemcitabine alone in platinum-resistant high grade serous ovarian cancer (HGSOC) by Konstantinopoulos, P.A., Wahner Hendrickson, A.E., Penson, R.T., Doyle, A., Kohn, E.C., Duska, L.R., Crispens, M.A., Olawaiye, A.B., Winer, I.S., Barroilhet, L.M., Fu, S., McHale, M.T., Schilder, R.J., Farkkila, A., Curtis, J., Quinn, R., Whalen, C., Shapiro, G.I., Matulonis, U.A.

“…HGSOCs exhibit genomic instability and high replication stress due to universal loss of the G1/S checkpoint (via TP53 mutations), presence of homologous…”
Get full text

Randomized phase II (RP2) study of ATR inhibitor M6620 in combination with gemcitabine versus gemcitabine alone in platinum-resistant high grade serous ovarian cancer (HGSOC) by Konstantinopoulos, P.A., Wahner Hendrickson, A.E., Penson, R.T., Doyle, A., Kohn, E.C., Duska, L.R., Crispens, M.A., Olawaiye, A.B., Winer, I.S., Barroilhet, L.M., Fu, S., McHale, M.T., Schilder, R.J., Farkkila, A., Curtis, J., Quinn, R., Whalen, C., Shapiro, G.I., Matulonis, U.A.

Get full text

Baseline platelet count and body weight as predictors of early dose modification in the quadra trial of niraparib monotherapy for the treatment of heavily pretreated (≥4th line), advanced, recurrent high-grade serous ovarian cancer by Matulonis, U.A., Monk, B.J., Secord, A.A., Geller, M.A., Miller, D.S., Cloven, N.G., Fleming, G.F., Hendrickson, A.E. Wahner, Azodi, M., DiSilvestro, P.A., Oza, A.M., Cristea, M., Berek, J.S., Chan, J.K., Li, Y., Luptakova, K., Hazard, S.J., Moore, K.N.

Get full text

Results of TRIO-14, a phase II, multicenter, randomized, placebo-controlled trial of carboplatin-paclitaxel versus carboplatin-paclitaxel-ganitumab in newly diagnosed epithelial ovarian cancer by Konecny, G.E., Hendrickson, A.E. Wahner, Davidson, T.M., Winterhoff, B.J., Ma, S., Mahner, S., Sehouli, J., Fasching, P.A., Feisel-Schwickardi, G., Poelcher, M., Roman, L.D., Rody, A., Karlan, B.Y., Mullany, S.A., Chen, H., Ray-Coquard, I.L., Provencher, D.M., Yachnin, A., Cottu, P.H., Glaspy, J.A., Haluska, P., Slamon, D.J.

“…Insulin-like growth factor (IGF) signaling is implicated in pathogenesis and chemotherapy resistance of epithelial ovarian cancer (EOC). We explored efficacy…”
Get full text

A phase II clinical trial of veliparib and topotecan in patients with platinum resistant ovarian cancer by Wahner Hendrickson, A.E., Costello, B., Jewell, A., Kennedy, V., Fleming, G., Corr, B., Taylor, S.E., Lea, J., Reid, J., Swisher, E., Satele, D., Allred, J., Lensing, J., Ivy, S.P., Erlichman, C., Adjei, A.A., Kaufmann, S.

Get full text

QUADRA: A phase II, open-label, single-arm study to evaluate niraparib in patients (pts) with relapsed ovarian cancer (ROC) in 4th or later line of therapy: Results from the tBRCAmut subset by Moore, K.N., Secord, A.A., Geller, M., Miller, D.S., Cloven, N.G., Fleming, G.F., Wahner Hendrickson, A.E., Azodi, M., DiSilvestro, P., Oza, A., Cristea, M., Berek, J.S., Chan, J.K., Rimel, B.J., Li, Y., Luptakova, K., Clark, R., Matulonis, U.A., Monk, B.J.

Get full text

Insulin receptor isoform expression in ovarian cancer in African American women by Ali-Fehmi, R, Cote, M.L, Harrington, S.C, Block, M.S, Hartmann, L.C, Maurer, M.J, Kalli, K.R, Haluska, P

Get full text